UBS Group’s Therapix Biosciences Ltd. TRPX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-41,428
| Closed | -$26K | – | 8830 |
|
|
2020
Q2 | $26K | Buy |
41,428
+35,962
| +658% | +$17.3K | ﹤0.01% | 6393 |
|
|
2020
Q1 | $2K | Buy |
5,466
+3,576
| +189% | +$2.03K | ﹤0.01% | 7699 |
|
|
2019
Q4 | $2K | Buy |
1,890
+1,559
| +471% | +$2.87K | ﹤0.01% | 7900 |
|
|
2019
Q3 | $1K | Buy |
+331
| New | +$837 | ﹤0.01% | 7913 |
|
|
2019
Q1 | – | Sell |
-4,612
| Closed | -$15K | – | 8439 |
|
|
2018
Q4 | $15K | Buy |
4,612
+3,030
| +192% | +$17.6K | ﹤0.01% | 7009 |
|
|
2018
Q3 | $7K | Buy |
1,582
+1,109
| +234% | +$4.3K | ﹤0.01% | 7371 |
|
|
2018
Q2 | $2K | Sell |
473
-2,427
| -84% | -$11K | ﹤0.01% | 7769 |
|
|
2018
Q1 | $17K | Buy |
+2,900
| New | +$16.7K | ﹤0.01% | 6529 |
|
|
2017
Q2 | – | Sell |
-230
| Closed | -$2K | – | 8164 |
|
|
2017
Q1 | $2K | Buy |
+230
| New | +$2.02K | ﹤0.01% | 7335 |
|
UBS Group's TRPX Position: Q3 2020 in Review
UBS Group sold out of Therapix Biosciences Ltd. (TRPX) in Q3 2020, closing a stake of 41,428 shares — an estimated $26K sold.
UBS Group first reported a position in TRPX in Q1 2017 and held it in 9 quarters. The position peaked at $26K in Q2 2020. 0 funds tracked by Wall St. Rank hold TRPX as of Q3 2020.
- UBS Group reported no remaining Therapix Biosciences Ltd. position as of Q3 2020 after selling out during the quarter.
- UBS Group sold 41,428 Therapix Biosciences Ltd. shares in Q3 2020, an estimated $26K.
- UBS Group first reported a position in Therapix Biosciences Ltd. in Q1 2017 and held it in 9 quarters.
- UBS Group's Therapix Biosciences Ltd. position peaked at $26K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Therapix Biosciences Ltd. as of Q3 2020.
Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.